BCM
STRO icon

Bridgeway Capital Management’s Sutro Biopharma STRO Stock Holding History

Bridgeway Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,290
Closed -$37.3K – 1280
2025
Q3 		$37.3K Buy
4,290
+3,000
+233% +$25.5K ﹤0.01% 1177
2025
Q2 		$9.21K Hold
1,290
– – ﹤0.01% 1176
2025
Q1 		$8.39K Sell
1,290
-17,680
-93% -$278K ﹤0.01% 1171
2024
Q4 		$349K Buy
18,970
+9,050
+91% +$276K 0.01% 890
2024
Q3 		$343K Sell
9,920
-9,650
-49% -$378K 0.01% 946
2024
Q2 		$573K Sell
19,570
-8,000
-29% -$316K 0.01% 830
2024
Q1 		$1.56M Buy
27,570
+10,550
+62% +$466K 0.03% 639
2023
Q4 		$730K Buy
+17,020
New +$540K 0.02% 838
2020
Q1 		– Sell
-5,720
Closed -$629K – 1353
2019
Q4 		$629K Buy
5,720
+840
+17% +$86.6K 0.01% 884
2019
Q3 		$444K Hold
4,880
– – 0.01% 1002
2019
Q2 		$555K Buy
+4,880
New +$538K 0.01% 945

Other funds holding STRO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Bridgeway Capital Management's STRO Position: Q4 2025 in Review

Bridgeway Capital Management sold out of Sutro Biopharma (STRO) in Q4 2025, closing a stake of 4,290 shares — an estimated $37.3K sold.

Bridgeway Capital Management first reported a position in STRO in Q2 2019 and held it in 11 quarters. The position peaked at $1.56M in Q1 2024. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

  • Bridgeway Capital Management reported no remaining Sutro Biopharma position as of Q4 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 4,290 Sutro Biopharma shares in Q4 2025, an estimated $37.3K.
  • Bridgeway Capital Management first reported a position in Sutro Biopharma in Q2 2019 and held it in 11 quarters.
  • Bridgeway Capital Management's Sutro Biopharma position peaked at $1.56M in Q1 2024.
  • 63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on Bridgeway Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.